What sermorelin acetate is, where the 29-residue fragment came from, how it acts at the GHRH receptor, how it compares with native GHRH, tesamorelin, CJC-1295 and ipamorelin, and how to handle it in the lab.
Sermorelin is the first 29 amino acids of human growth hormone-releasing hormone (GHRH), with an amidated C-terminus. It is usually supplied as sermorelin acetate, where acetate is simply the counter-ion left from purification rather than part of the peptide itself. Because it is the shortest synthetic sequence reported to retain the full biological activity of GHRH [8], sermorelin has long served as a reference agonist for the GHRH receptor and as a starting point for the longer-lived analogues that followed. This guide covers where the fragment came from, what it does at the receptor, how it differs from related secretagogues, and the practical points that matter when it is used in a laboratory.
GHRH was first characterized not from the hypothalamus but from pancreatic tumors in patients with acromegaly. In 1982 Guillemin's group reported a 44-amino-acid peptide from such a tumor whose synthetic replicate had full growth hormone-releasing activity in vitro and in vivo [5], and Rivier, Vale and colleagues independently characterized a related 40-residue form [6]. Soon after, a synthetic 40-residue form given to six healthy men raised serum GH within 5 minutes without increasing prolactin, TSH, LH or cortisol, which established its selectivity for GH in humans [2]. In 1984 the peptide isolated from human hypothalamic tissue proved identical in sequence to the 44-residue tumor peptide [1].
Structure-activity work then showed that the N-terminal 29 residues carry the activity of the whole hormone. That fragment, GHRH(1-29)-NH2, is sermorelin [8].
The acetate salt matters when you weigh material. The mass of lyophilized powder includes counter-ion and residual water, so the net peptide content is lower than the gross weight. For quantitative work, concentrations are best calculated from net peptide content or confirmed analytically.
The human GHRH receptor was cloned from pituitary tissue in 1993. It is a 423-amino-acid G protein-coupled receptor in the secretin family, sharing 47% identity with the VIP receptor. When expressed in COS cells it produced saturable, high-affinity, GHRH-specific binding and cAMP accumulation, both blocked by a GHRH antagonist, and its mRNA was most abundant in pituitary extracts [7]. That cell system is essentially the template for modern in-vitro sermorelin work: receptor-expressing cells, a binding readout and a cAMP readout.
Downstream, GHRH-receptor signaling in somatotrophs drives both GH gene transcription and GH release. The product page describes the Gs, cAMP and PKA cascade in more detail. The point worth stressing here is where sermorelin sits in the axis: it acts upstream of the pituitary, so somatostatin can still restrain the response and IGF-1 feedback remains intact. Reviews of aging research have noted that GHRH administration was reported to maintain the pulsatile pattern of GH secretion in older men, which is the main reason GHRH-based tools are used when pulsatility is the variable of interest [4].
A 1986 study incubated GHRH(1-44)-NH2 with human plasma and followed it by HPLC. The intact peptide disappeared with a half-life of 17 minutes and was converted to GHRH(3-44)-NH2, which retained less than one-thousandth of the biological activity. After intravenous administration to healthy volunteers, the half-life of the intact peptide was 6.8 minutes. The authors attributed this to a plasma dipeptidyl aminopeptidase, the enzyme now known as DPP-4 [9].
That study used the 44-residue hormone, but sermorelin carries the same Tyr-Ala N-terminus, so the same cleavage is expected to apply. This single observation explains much of the chemistry that followed: most later GHRH analogues were designed either to block this cleavage or to extend circulation time by other means.
Sermorelin and full-length GHRH act at the same receptor and share the same vulnerable N-terminus. The practical differences are size (about 3.4 kDa versus 5 kDa) and cost of synthesis, which is one reason the shorter fragment became the more common research reagent.
Tesamorelin is full-length GHRH(1-44)-NH2 with a trans-3-hexenoyl group added to Tyr1 to resist DPP-4. Unlike sermorelin, it has an extensive human clinical record and an approved drug form. Our tesamorelin research overview covers it in detail.
CJC-1295 is a GHRH analogue built to last far longer. In two randomized, placebo-controlled trials in healthy adults, a single administration raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days [12]. That profile is useful when sustained exposure is the goal, and a poor fit when a study needs discrete, short-lived pulses, which is where sermorelin remains the simpler tool. Note that the peptide often sold as "CJC-1295 without DAC" is a different, modified GHRH(1-29) and lacks the long-acting group studied in that trial.
Growth hormone-releasing peptides act at a different receptor, the ghrelin receptor (GHS-R1a), rather than at the GHRH receptor. In 18 healthy men, submaximal amounts of the hexapeptide GHRP given together with GHRH produced synergistic GH release, which the investigators took as evidence that the two act through independent mechanisms [10]. Ipamorelin, a pentapeptide from the same line of chemistry, released GH from primary rat pituitary cells with potency similar to GHRP-6. In swine it did not raise ACTH or cortisol, whereas GHRP-6 and GHRP-2 did [11]. For experimental design, this means a GHRH agonist such as sermorelin and a GHS-R agonist such as ipamorelin are complementary probes of two separate inputs to the somatotroph, not interchangeable ones.
Much of the human sermorelin literature dates from its development as a pharmaceutical. A 1999 review describes its use as a provocative test for GH deficiency and in children with idiopathic GH deficiency. It reports that increases in height velocity were sustained over 12 months in those studies, and that height-velocity gains were smaller than those reported with somatropin, although the two had not been compared directly [8]. A branded form, Geref, was marketed in the United States and was later discontinued by its manufacturer. The research material sold by Northbridge Research Labs is not that product and is not intended for any clinical use.
A second strand concerns aging. A review of GH and aging summarized that spontaneous and stimulated GH secretion, IGF-1 and IGFBP-3 all decline with advancing age [4]. In a six-week study of 11 healthy men aged 64 to 76 with low baseline IGF-1, GHRH(1-29) given once each night increased mean nocturnal GH release, GH peak area and peak amplitude, with no change in pulse frequency, IGF-1, body composition or lipids. Two of six strength measures improved, and the authors suggested that a single nightly administration was less effective than multiple administrations for GH- and IGF-1-mediated effects [3]. These are small human studies with specific designs, and they are best read as data on GH-axis responsiveness rather than as outcomes that carry over to other settings.
Northbridge Research Labs sends every batch for independent third-party testing, and the certificates of analysis we have published are available on our COA page. Our peptide storage and handling guide covers general technique in more depth.
Note: Sermorelin acetate from Northbridge Research Labs is supplied for laboratory research use only. It is not a drug and is not for human or veterinary use. The human studies summarized above are reported as published findings and are not guidance for any use.
Studied compound
Sermorelin Acetate
The same material this research covers — 99%+ purity, independently tested, with the certificate for each batch published online.
How a single trans-3-hexenoyl group turns native GHRH into a longer-lived analogue, what the phase 3 and liver-fat trials actually found, what preclinical work showed, and how to handle tesamorelin in the lab.
How retatrutide-type triple agonism at the GLP-1, GIP and glucagon receptors was designed, what the published rodent and phase 2 literature reports, and which questions remain open for laboratory study.
The receptor biology behind tirzepatide-type dual GIP and GLP-1 receptor agonism, what 'imbalanced and biased' agonism means, what the SURPASS and SURMOUNT trials reported, and how dual agonism differs from triple.
Research Use Only: The information in this article is for educational and research purposes only. All products mentioned are intended for laboratory research use only and are not approved for human or veterinary use.